Houston, Texas —Speratum Biopharma, Inc. (“Speratum”), a Houston-based precision oncology company developing next-generation RNA-based therapeutics, is proud to announce that it has been named a winner at the Global Fast Track 2025 (GFT 2025) programme, held during Hong Kong FinTech Week × StartmeupHK Festival 2025.

The recognition highlights Speratum’s innovative RNA-based therapeutic platforms and its commitment to advancing precision oncology worldwide. Organized by Invest Hong Kong (InvestHK), GFT 2025 connects high-growth technology companies with leading investors and corporates across Asia.

“We’re honored to be recognized at Global Fast Track 2025,” said Dr. Christian Marín-Müller, Founder & CEO of Speratum. “This award validates our mission to deliver transformative RNA-based cancer therapeutics and expand our global impact.”